IGC - IGC Pharma Inc Market Capitalization-to-Revenue Ratio

Symbol and logo of brand IGC Pharma, Inc. (IGC)

IGC Pharma, Inc. (IGC) is developing a closed-loop cannabinoid-based therapy system for Alzheimer's disease, which ensures high profit scalability through patents during mass drug production. The current P/S ratio reflects the business valuation trend, with the metric standing at 16.00. However, the risk of prolonged testing and potential secondary offerings to combat losses are creating pressure on capital.

India Globalization Capital (IGC) - P/S Multiple from 07/04/2022 to 11/14/2026

Metric breakdowns and analytics for India Globalization Capital (IGC)

- market price and analyst price targets:
Stock Quotes IGC Pharma Inc|IGC - Consensus Target
- market capitalization statistics:
Market Value IGC Pharma|IGC - Total Company Value
- book capitalization indicators:
Share Book Value IGC Pharma|IGC - Book Capitalization|Market Value to Book Value igcinc.us|IGC - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital IGC Pharma, Inc.|IGC - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital India Globalization Capital|IGC - Company Debts|Debt to Book Value IGC|IGC - Company Long-Term Debts|Company Short-Term Debts IGC Pharma|Intermediate Coverage Ratio igcinc.us
- earnings and valuation multiples indicators:
IGC - Net Profit|Company Profit Forecast IGC Pharma, Inc.|IGC - Price to Earnings Ratio|Price to Future Earnings Ratio IGC Pharma|IGC - PEG Multiple|Enterprise Value to EBITDA Ratio IGC Pharma, Inc.|IGC - Operating profit before deduction of amortization|Net earnings per share for the last four quarters IGC Pharma|IGC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months igcinc.us|IGC - Earnings growth in current year|Net earnings per one share growth forecast for next year IGC Pharma, Inc.
- issuer revenue and sales details:
IGC - Revenue and Sales Volume|Company Future Sales Volume India Globalization Capital|IGC - Price-to-Revenue Ratio|Market Cap to Projected Revenue IGC
Fundamental company analysis:IGC (IGC Pharma Inc)
Signature product of IGC Pharma

IGC Pharma, Inc. (IGC) maintains a strong position thanks to a unique patent portfolio in Alzheimer's disease therapy. The price-to-sales ratio quantifies the premium the market is willing to pay for this exclusive access to innovation. This metric determines the value of every dollar of revenue, making it possible to distinguish fundamental growth from speculative noise. Analyzing the business valuation via P/S helps investors recognize the risk of overpaying for assets in a timely manner.

Competing companies

Indivior - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Collegium Pharmaceutical Inc COLL|Cronos Corp (CRON) - Price to Sales|CGC - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio HITI (High Tide)|ACB: P/S Multiple|Price to Sales Achieve Life Sciences, Inc (ACHV)|SKYE (Skye Bioscience, Inc.) - P/S Multiple|Price-to-Revenue Ratio ANEB|Market Cap to Revenue INCR (intercure.co)|P/S Multiple Nutriband Inc (NTRB)|P/S Multiple NSRX (Nasus Pharma Ltd)|P/S Multiple MIRA Pharmaceuticals MIRA|FLGC - Price-to-Revenue Ratio|IMCC: Price-to-Revenue Ratio|Adial (ADIL) - Price-to-Revenue Ratio|Price to Sales Artelo (ARTL)|Price-to-Revenue Ratio Ensysce Biosciences Inc.|Market Cap to Revenue Titan Pharmaceuticals (TTNP)|Price-to-Revenue Ratio gnln.com (GNLN)|Market Cap to Revenue InMed Pharma INM|Price-to-Revenue Ratio Akanda AKAN|ENVB - Market Cap to Revenue|brightgreen.us - P/S Multiple|Price-to-Revenue Coefficient hempaccoinc.com HPCO